Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Satellos Bioscience Inc (MSCL.TO)

Satellos Bioscience Inc (MSCL.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 226,484
  • Shares Outstanding, K 20,627
  • Annual Sales, $ 0 K
  • Annual Income, $ -19,579 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.08
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.05
  • Number of Estimates 1
  • High Estimate -0.05
  • Low Estimate -0.05
  • Prior Year -0.06
  • Growth Rate Est. (year over year) +16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.44 +5.17%
on 03/10/26
18.98 -42.15%
on 03/03/26
-4.76 (-30.24%)
since 02/13/26
3-Month
7.56 +45.24%
on 12/23/25
18.98 -42.15%
on 03/03/26
+2.94 (+36.57%)
since 12/12/25
52-Week
6.24 +75.96%
on 06/17/25
18.98 -42.15%
on 03/03/26
+0.18 (+1.67%)
since 03/13/25

Most Recent Stories

More News
Stocks in play: Satellos Bioscience Inc.

Today announced interim clinical and biomarker data for SAT-3247 at the Muscular Dystrophy Association ...

MSCL.TO : 10.98 (-4.94%)
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater improvements...

MSLE : 8.00 (-6.54%)
MSCL.TO : 10.98 (-4.94%)
Stocks in play: Satellos Bioscience Inc.

Will present two oral scientific presentations and three posters at the 2026 Muscular Dystrophy Association ...

MSCL.TO : 10.98 (-4.94%)
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases,...

MSLE : 8.00 (-6.54%)
MSCL.TO : 10.98 (-4.94%)
Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy

Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle...

MSLE : 8.00 (-6.54%)
MSCL.TO : 10.98 (-4.94%)
Satellos to Participate in Upcoming Investor Conferences

Satellos Bioscience Inc. (Nasdaq: MSLE , TSX: MSCL ) (“Satellos” or the “Company”), a clinical-stage biotechnology company focused on restoring natural muscle...

MSLE : 8.00 (-6.54%)
MSCL.TO : 10.98 (-4.94%)
Stocks in play: Satellos Bioscience Inc.

Today announced that the first participant has been dosed in BASECAMP, a three-month, randomized, double-blind, ...

MSCL.TO : 10.98 (-4.94%)
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy

BASECAMP, a three-month, randomized, double-blind, placebo-controlled study, will evaluate SAT-3247’s safety and tolerability, and effect on muscle force, muscle quality and muscle regeneration

MSCLF : 0.9230 (+1.41%)
MSCL.TO : 10.98 (-4.94%)
Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Satellos Bioscience Inc. (Nasdaq: MSLE , TSX: MSCL ) (“Satellos” or the “Company”), a clinical-stage biotechnology company focused on restoring natural muscle...

MSLE : 8.00 (-6.54%)
MSCL.TO : 10.98 (-4.94%)
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares

Satellos Bioscience Inc . (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle...

MSLE : 8.00 (-6.54%)
MSCL.TO : 10.98 (-4.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne...

See More

Key Turning Points

3rd Resistance Point 12.57
2nd Resistance Point 12.16
1st Resistance Point 11.57
Last Price 10.98
1st Support Level 10.57
2nd Support Level 10.16
3rd Support Level 9.57

See More

52-Week High 18.98
Fibonacci 61.8% 14.11
Fibonacci 50% 12.61
Fibonacci 38.2% 11.11
Last Price 10.98
52-Week Low 6.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar